Last reviewed · How we verify
NCT05534776
Validation of 5-Point Investigator Global Assessments for Pemphigus
trial testing Investigator Global Assessments (IGAs) in Pemphigus in 40 participants. Status unknown.
30 August 2023
Quick facts
| Lead sponsor | Premier Specialists, Australia |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 21 September 2022 |
| Primary completion | 30 August 2023 |
| Estimated completion | 30 August 2023 |
| Sites | 7 locations across Greece, Israel, Bulgaria, Australia, Singapore, Iran, Turkey (Türkiye) |
Drugs / interventions tested
- Investigator Global Assessments (IGAs)
Conditions studied
- Pemphigus — all drugs for Pemphigus →
Sponsor
Premier Specialists, Australia — full company profile →
Who can join
18 and older, any sex, with Pemphigus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to explore the reliability and validity of newly developed Investigator Global Assessments (IGAs) in scoring the severity of pemphigus. IGAs are simple 5-point scales ranging from clear - severe and are preferred by the FDA as endpoints in clinical trials.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05534776
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pemphigus
Currently open trials in the same condition.
- NCT05898308 — Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus · Phase 4 · recruiting
- NCT06454357 — A Clinical Study of B007 in the Treatment of Pemphigus. · Phase 2, PHASE3 · recruiting
- NCT06696716 — ONO-4059 Study in Patients With Steroid-resistant Pemphigus · Phase 3 · recruiting
- NCT04400994 — IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus · Phase 2 · active not recruiting
- NCT05954416 — FARD (RaDiCo Cohort) (RaDiCo-FARD) · recruiting
Other Premier Specialists, Australia trials
Trials by the same sponsor.
- NCT06032078 — Evaluation of the Responsiveness of Investigator Global Assessment Score for Keratosis Pilaris · NA · unknown
- NCT05535517 — Development and Validation of an Investigator Global Assessment Score for Keratosis Pilaris · unknown
- NCT04971200 — Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo · EARLY_PHASE1 · completed
- NCT05525065 — Investigating the Morbidity of Glucocorticoid Use in Patients With Autoimmune Bullous Diseases (AIBDs) · unknown
- NCT07228481 — Study of Two Dosages of Roaccutane in Cystic Acne · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05534776 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Premier Specialists, Australia
- Last refreshed: 19 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05534776.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing